^
Association details:
| Biomarker: | ASNS underexpression |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | IPN60090 (Glutaminase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
New Therapy for Lung and Ovarian Cancer Advances to Early-stage Clinical Development
Published date:
04/27/2020
Excerpt:
IPN60090 currently is under investigation in a Phase I dose-escalation and dose-expansion study for patients with advanced solid tumors that harbor KEAP1/NFE2L2 mutations or have low ASNS levels. Initial data from the clinical trial indicate that IPN60090 is effectively inhibiting GLS1 activity in peripheral blood.mononuclear cells from patients.
